Abstract
Patents are based on a delicate policy to promote technological progress by incentivising the inventor and enabling others to participate in the innovation process through public disclosure. Patent being a property does not fit in the rigid proprietary framework, given its goal to promote the public good. The limits to patent rights on one hand and duties and obligations on the other complement patent rights, enabling the system to promote social good. However, in practice, an aggressive assertion of patent rights often ignores the duties and obligations recognised under the patent system. The “exclusivity” of patents imposes a duty on third parties to respect the patentee’s patent rights. However, while recognising the duties and obligations of the patentee, the patent systems put less emphasis on it in practice. Though limits to patent rights such as research exemptions, compulsory licences and governmental use are recognised statutorily and judicially, an appreciation of duties and obligations may produce a more pragmatic result. In the current pandemic situation, open and collaborative efforts such as Open COVID Pledge, non-assertion of exclusive rights on technologies and research tools assisting in the vaccine production reflect promising approaches. Nevertheless, the challenges as the accessibility and affordability of the potential vaccine are still on. Gandhi’s perspective on trusteeship could be contextualised in the patent realm to promote a duty-based regime in tune with the broader goals of patent policy. Against this backdrop, the present chapter explores the edifice and relevance of duties and obligations under the patent system in the light of contemporary challenges.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
A. Smith (1762–3) Lectures on Jurisprudence, Glasgow Edition of the Works of Adam Smith (eds.) R. L. eek, D. D. Raphael and P. Stein, Oxford: Oxford University Press, 1978 quoted in Helen Gubby, “Is the Patent stem a Barrier to Inclusive Prosperity? The Biomedical Perspective” 11:1 Global Policy 46–55 (2019) Available at https://onlinelibrary.wiley.com/doi/full/10.1111/1758-5899.12730 (last visited October 12, 2021).
- 2.
J. Bentham (1843) ‘The Works of Jeremy Bentham’, in J. Bowring (ed.), A Manual of Political Economy, Chap. 3, Vol. 3, Section 23. Edinburgh: Bowring Edition p.71 quoted in Helen Gubby, “Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective” 11:1 Global Policy 46–55 (2019) Available at https://onlinelibrary.wiley.com/doi/full/10.1111/1758-5899.12730 (last visited October 12, 2021).
- 3.
See Jonathan M. Barnett, “The Patent System At a Crossroads” Regulation 44–47 (Spring, 2018) available at ttps://www.cato.org/sites/cato.org/files/serials/files/regulation/2018/3/regulation-v41n1-2.pdf (last visited October 12, 2021).
- 4.
Srividhya Ragavan, “Correlative Obligation in Patent Law: The Role of Public Good in Defining the Limits of Patent Exclusivity” 6 The NYU Journal of Intellectual Property & Entertainment Law 47 (2016). Available at: https://scholarship.law.tamu.edu/facscholar/806 (last visited October 12, 2021).
- 5.
Adam Mossoff, “Exclusion and exclusive use in patent law” 22:2 Harvard Journal of Law & Technology 321–379 (Spring 2009). Available at http://jolt.law.harvard.edu/articles/pdf/v22/22HarvJLTech321.pdf (last visited October 12, 2021).
- 6.
Ibid.
- 7.
Ragavan, supra note 4.
- 8.
Ibid.
- 9.
Shamnad Basheer, “Making patents work: of IP duties and deficient disclosure” 7:1 Queen Mary Journal of Intellectual Property 3–24 (2017) available at https://www.elgaronline.com/view/journals/qmjip/7-1/qmjip.2017.01.01.xml?pdfVersion=true (last visited October 12, 2021).
- 10.
Ibid.
- 11.
Ragavan, supra note 4.
- 12.
Mossoff, supra note 5.
- 13.
Basheer, supra note 9.
- 14.
Ibid.
- 15.
Ibid.
- 16.
Mossoff, supra note 5.
- 17.
Ibid.
- 18.
Ibid.
- 19.
Ibid.
- 20.
Ibid.
- 21.
Basheer, supra note 9.
- 22.
Ibid.
- 23.
Ibid. (See Section 146(1) and 146(2) of the Patents Act 1970).
- 24.
Ibid.
- 25.
Mossoff, supra note 5.
- 26.
Mario Biagioli, “Weighing intellectual property: Can we balance the social costs and benefits of patenting?” 57:1 History of Science 140–163 (2019). Available at https://journals.sagepub.com/doi/pdf/10.1177/0073275318797787 (last visited October 12, 2021).
- 27.
Ibid.
- 28.
Ibid.
- 29.
Ragavan, supra note 4.
- 30.
Ibid.
- 31.
A. Samuel Oddi, “Plagues, Pandemics, and Patents: Legality and Morality” 51:1 IDEA-The Intellectual Property Law Review 1–45 (2011). Available at https://www.ipmall.info/sites/default/files/hosted_resources/IDEA/idea-vol51-no1-oddi.pdf (last visited October 12, 2021).
- 32.
Dennis D. Crouch, “Nil: The Value of Patents in A Major Crisis Such As an Influenza Pandemic” 39 Seton Hall Law Review 1125–1136 (2009) Available at https://scholarship.law.missouri.edu/facpubs/431/ (last visited October 12, 2021).
- 33.
Oddi, supra note 31.
- 34.
Phoebe Li (2013) “Rights and responsibilities in patents: a precautionary patent framework in WTO law” 35:9 European Intellectual Property Review 516–26 (2013). Available at https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2667867 (last visited October 12, 2021).
- 35.
Oddi, supra note 31.
- 36.
Li, supra note 34.
- 37.
See Article 27.2 of the TRIPS Agreement.
- 38.
See Article 31 of the TRIPS Agreement.
- 39.
Paragraph 4 of the Doha Declaration on the TRIPS Agreement and Public Health, 2001.
- 40.
Ibid.
- 41.
See paragraph 5 (b) of the Doha Declaration on the TRIPS Agreement and Public Health, 2001.
- 42.
Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, 2001.
- 43.
See Article 31(f) and 31bis of the TRIPS Agreement; and WTO General Council Amendment of the TRIPS Agreement (Decision of 6 December 2005) WT/L/641 8 DECEMBER 2005 available at https://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm (last visited on October 12, 2021).
- 44.
See Article 31 of the TRIPS Agreement generally and Article 31(f), 31(h) and 31bis specifically.
- 45.
Oddi, supra note 31.
- 46.
Ibid.
- 47.
Ibid.
- 48.
Ana Santos Rutschman, “The Intellectual Property of COVID-19” (September 11, 2020). Forthcoming in Outsmarting Pandemics, Elizabeth Kirley & Deborah Porter (Eds.) (2021), Saint Louis University Legal Studies Research Paper Series 2020–28. Available at https://scholarship.law.slu.edu/faculty/533/ (last visited October 12, 2021).
- 49.
Dennis D. Crouch, “Nil: The Value of Patents in A Major Crisis Such As an Influenza Pandemic” 39 Seton Hall Law Review 1125–1136 (2009) Available at https://scholarship.law.missouri.edu/facpubs/431/ (last visited October 12, 2021).
- 50.
Ibid.
- 51.
MSF Briefing Document, May 2021: Compulsory Licenses, The TRIPS Waiver and Access to COVID-19 Medical Technologies, available at https://msfaccess.org/compulsory-licenses-trips-waiver-and-access-covid-19-medical-technologies (last visited October 12, 2021).
- 52.
Rutschman, supra note 48.
- 53.
Hyo Yoon Kang, “COVID-19: Who Is the ‘Public’ in IP Law That Defines Its Public Purpose? Science-The Wire, 07/03/2021 Available at https://science.thewire.in/health/covid-19-who-is-the-public-in-ip-law-that-defines-its-public-purpose/ (last visited October 12, 2021).
- 54.
Ibid.
- 55.
Ibid.
- 56.
Ibid.
- 57.
Ibid.
- 58.
Hilary Wong, “The case for compulsory licensing during COVID-19” 10:1 Journal of global health (2020) Available at https://jogh.org/documents/issue202001/jogh-10-010358.pdf (last visited October 12, 2021).
- 59.
Supra note 51.
- 60.
Wong, supra note 58.
- 61.
Shukadev Khuraijam, “Positive outlook for India’s patent regime in a pandemic age” Managing IP 23 September 2021. Available at https://www.managingip.com/article/b1tq527x8x9p4n/positive-outlook-for-indias-patent-regime-in-a-pandemic-age (last visited October 12, 2021).
- 62.
Ibid.
- 63.
Wong, supra note 58.
- 64.
Rutschman, supra note 48.
- 65.
Jorge L. Contreras, Michael Eisen, Ariel Ganz et al., “Pledging intellectual property for COVID-19” 38 Nature Biotechnology 1114–1149 (2020). Available at https://www.nature.com/articles/s41587-020-0682-1#citeas (last visited October 12, 2021).
- 66.
Kang, supra note 53.
- 67.
Ibid.
- 68.
Ibid. (For example, ‘Pfizer/BioNTech have chosen to keep vaccine information secret; BioNTech has previous patents in mRNA technology’).
- 69.
World Health Organisation: “COVAX-With a fast-moving pandemic, no one is safe, unless everyone is safe” available at https://www.who.int/initiatives/act-accelerator/covax (last visited October 12, 2021).
- 70.
Rosa Furneaux & Olivia Goldhill, “‘Naïvely Ambitious’: How COVAX Failed on Its Promise to Vaccinate the World” Science-The Wire 09/10/2021. Available at https://science.thewire.in/health/naively-ambitious-how-covax-failed-on-its-promise-to-vaccinate-the-world/ (last visited October 12, 2021).
- 71.
Ibid.
- 72.
Ibid.
- 73.
Ibid.
- 74.
Rutschman, supra note 48.
- 75.
UNICEF Statement: “No-one is safe until everyone is safe—why we need a global response to COVID-19” 24 May 2021 available at https://www.unicef.org/press-releases/no-one-safe-until-everyone-safe-why-we-need-global-response-covid-19 (last visited October 12, 2021).
- 76.
“Countries obstructing COVID-19 patent waiver must allow negotiations to start” relief web 09/03/202. Available at https://reliefweb.int/reportworld/coutries-obstructing-covid-19-patent-waiver-must-allow-negotiations-start (last visited October 12, 2021).
- 77.
WTO Council for Trade-Related Aspects of Intellectual Property Rights: “Waiver from certain provisions of the trips agreement for the prevention, containment and treatment of Covid-19”-communication from India and South Africa, IP/C/W/669 2 October 2020. Available at https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/IP/C/W669.pdf (last visited October 12, 2021).
- 78.
Ibid.
- 79.
Ibid.
- 80.
Andrew Green, “Where are we on COVID-19 after a year of TRIPS waiver negotiations?” devex 7 October 2021 Available at https://www.devex.com/news/where-are-we-on-covid-19-after-a-year-of-trips-waiver-negotiations-101795 (last visited October 12, 2021).
- 81.
Ibid.
- 82.
Supra note 77.
- 83.
Supra note 76.
- 84.
Ibid.
- 85.
Ibid.
- 86.
Ibid.
- 87.
“WHO Director-General’s speech at the Paris Peace Forum Panel: ACT-A: Covid-19 Vaccines, Tests and Therapies, the Global public good Solution- 12 November 2020”. Available at https://www.who.int/director-general/speeches/detail/who-director-general-s-speech-at-the-paris-peace-forum-panel-act-a-covid-19-vaccines-tests-and-therapies-the-global-public-good-solution---12-november-2020 (last visited October 12, 2021).
- 88.
See Rebecca Robbins, “Moderna, Racing for Profits, Keeps Covid Vaccine Out of Reach of Poor” The New York Times 9 October 2021. Available at https://www.nytimes.com/2021/10/09/business/moderna-covid-vaccine.html (last visited October 12, 2021).
- 89.
Kang, supra note 53.
- 90.
Ibid.
- 91.
“UNESCO calls for COVID-19 vaccines to be considered a global public good” 24/02/2021. Available at https://en.unesco.org/news/unesco-calls-covid-19-vaccines-be-considered-global-public-good (last visited October 12, 2021).
- 92.
S. Neethu, “Gandhi, Trusteeship and Intellectual Property Law” Global Trust 24/12/2013. Available at http://globaltrust.tau.ac.il/gandhi-trusteeship-and-intellectual-property-law/ (last visited October 12, 2021).
- 93.
Ibid.
- 94.
Ibid. (referring to Harijan, 31–3-1946, pp. 63–64).
- 95.
Neethu, supra note 92.
- 96.
Ibid.
- 97.
Ibid.
- 98.
Ibid.
- 99.
Ibid.
- 100.
G. N. Sarma, “Gandhi’s Concept of Duty”. 41:2 The Indian Journal of Political Science, Indian Political Science Association 214–231 (1980) Available at http://www.jstor.org/stable/41855023 (last visited October 12, 2021).
- 101.
Thomas Weber & Dennis Dalton, “Gandhi and the Pandemic” 55:25 Economic and Political Weekly (20 June 2020). Available at https://www.epw.in/journal/2020/25/perspectives/gandhi-and-pandemic.html (last visited October 12, 2021). See also Dilip Datta, “Gandhi and an epidemic” The Statesman 20/10/2020. Available at https://www.thestatesman.com/opinion/gandhi-and-an-epidemic-1502929764.html (last visited October 12, 2021).
References
Barnett JM (2018, Spring) The patent system at a crossroads. Regulation 44–47. Available at https://www.cato.org/sites/cato.org/files/serials/files/regulation/2018/3/regulation-v41n1-2.pdf. Last visited 12 Oct 2021
Basheer S (2017) Making patents work: of IP duties and deficient disclosure. Queen Mary J Intellect Prop 7:3–24. Available at last visited 12 Oct 2021
Biagioli M (2019) Weighing intellectual property: can we balance the social costs and benefits of patenting? History of Science 57:140–163 (2019). Available at https://journals.sagepub.com/doi/pdf/https://doi.org/10.1177/0073275318797787. Last visited 12 Oct 2021
Contreras JL, Eisen M, Ganz A et al (2020) Pledging intellectual property for COVID-19. Nat Biotechnol 38:1114–1149. Available at https://www.nature.com/articles/s41587-020-0682-1#citeas. Last visited 12 Oct 2021
Crouch DD (2009) Nil: the value of patents in a major crisis such as an influenza pandemic Seton Hall Law Rev 39:1125–1136. Available at https://scholarship.law.missouri.edu/facpubs/431/. Last visited 12 Oct 2021
Datta D (2021, October 20) Gandhi and an epidemic. The Statesman. Available at https://www.thestatesman.com/opinion/gandhi-and-an-epidemic-1502929764.html. Last visited 12 Oct 2021
Furneaux R, Goldhill O (2021, October 9) ‘Naïvely Ambitious’: how COVAX failed on its promise to vaccinate the world. Science-The Wire. Available at https://science.thewire.in/health/naively-ambitious-how-covax-failed-on-its-promise-to-vaccinate-the-world/. Last visited 12 Oct 2021
Green A (2021, October 7) Where are we on COVID-19 after a year of TRIPS waiver negotiations? devex. Available at https://www.devex.com/news/where-are-we-on-covid-19-after-a-year-of-trips-waiver-negotiations-101795. Last visited 12 Oct 2021
Gubby H (2019) Is the patent system a barrier to inclusive prosperity? The biomedical perspective. Glob Policy 11:46–55. Available at https://onlinelibrary.wiley.com/doi/full/https://doi.org/10.1111/1758-5899.12730. Last visited 12 Oct 2021
Kang HY (2021) COVID-19: who Is the ‘Public’ in IP law that defines its public purpose? Science-the wire 07/03/2021. Available at https://science.thewire.in/health/covid-19-who-is-the-public-in-ip-law-that-defines-its-public-purpose/. Last visited 12 Oct 2021
Khuraijam S (2021) Positive outlook for India’s patent regime in a pandemic age. Managing IP 23 September 2021. Available at https://www.managingip.com/article/b1tq527x8x9p4n/positive-outlook-for-indias-patent-regime-in-a-pandemic-age. Last visited 12 Oct 2021
Li P (2013) Rights and responsibilities in patents: a precautionary patent framework in WTO law. Eur Intellect Property Rev 35:516–26. Available at https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2667867. Last visited 12 Oct 2021
Mossof A (2009, Spring) Exclusion and exclusive use in patent law. Harvard J Law Technol 22:321–379. Available at http://jolt.law.harvard.edu/articles/pdf/v22/22HarvJLTech321.pdf. Last visited 12 Oct 2021
Neethu S (2013, December 24) Gandhi, trusteeship and intellectual property law. Glob Trust. Available at http://globaltrust.tau.ac.il/gandhi-trusteeship-and-intellectual-property-law/. Last visited 12 Oct 2021
Oddi SA (2011) Plagues, pandemics, and patents: legality and morality. IDEA Intellect Property Law Rev 51:1–45. Available at https://www.ipmall.info/sites/default/files/hosted_resources/IDEA/idea-vol51-no1-oddi.pdf. Last visited 12 Oct 2021
Ragavan S (2016) Correlative obligation in patent law: the role of public good in defining the limits of patent exclusivity. New York University J Intellect Property Entertain Law 6:47. Available at https://scholarship.law.tamu.edu/facscholar/806. Last visited 12 Oct 2021
Robbins R (2021, October 9) Moderna, racing for profits, keeps Covid vaccine out of reach of poor. The New York Times. Available at https://www.nytimes.com/2021/10/09/business/moderna-covid-vaccine.html. Last visited 12 Oct 2021
Rutschman AS (2020) The intellectual property of COVID-19 (September 11, 2020). Forthcoming in outsmarting pandemics. In: Kirley E, Porter D (eds) Saint Louis University legal studies research paper series 2020–28. Available at https://scholarship.law.slu.edu/faculty/533/. Last visited 12 Oct 2021
Sarma GN (1980) Gandhi’s concept of duty. Indian J Polit Sci (Indian Political Science Association) 41:214–231.Available at http://www.jstor.org/stable/41855023. Last visited 2 Oct 2021
Weber T, Dalton D (2020, June) Gandhi and the pandemic. Econ Polit Wkly 55. Available at https://www.epw.in/journal/2020/25/perspectives/gandhi-and-pandemic.html. Last visited 2 Oct 2021
Wong H (2020) The case for compulsory licensing during COVID-19. J Glob Health 10. Available at https://jogh.org/documents/issue202001/jogh-10-010358.pdf. Last visited 12 Oct 2021
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Singh, K.K. (2022). Patent and Pandemic: Exploring Duties, Obligations and Responsibilities. In: Mittal, R., Singh, K.K. (eds) Relevance of Duties in the Contemporary World. Springer, Singapore. https://doi.org/10.1007/978-981-19-1836-0_26
Download citation
DOI: https://doi.org/10.1007/978-981-19-1836-0_26
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-1835-3
Online ISBN: 978-981-19-1836-0
eBook Packages: Social SciencesSocial Sciences (R0)